Muzero Acquisition

Establishes the SPAC's trust structure ($10.00 per share initially), redemption mechanics, deadline, and sponsor incentives. Investors can now evaluate the offering terms, dilution from founder shares, and the management team's background. The filing is material to tracking the SPAC's pre-deal mechanics.

What changed: Form 8-K Current Report and accompanying press release announcing the separate trading commencement for Muzero Acquisition Corp’s public units. Per Item 8.01 and Exhibit 99.1, the Company announced that, commencing March 23, 2026, holders of units traded under the symbol MUZEU may elect to separately trade the Class A ordinary shares and warrants included in those units, which will begin trading under the symbols MUZE and MUZEW, respectively. Each whole warrant entitles the holder to purchase one Class A ordinary share at an exercise price of $11.50 per share. The filing states that no fractional warrants will be issued upon separation and that holders must direct their brokers to contact Continental Stock Transfer & Trust Company to effect the split. The document contains no updates regarding the redemption calendar, trust account valuation or composition, business combination deadline, extension voting, or sponsor governance or conduct. Why it matters: The attached press release outlines the Company’s structural posture and strategic direction. According to the press release prepared by the Company, Muzero Acquisition Corp was organized as a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. Management disclosed that while the charter permits pursuing a transaction in ‘any business or industry or at any stage of its corporate evolution,’ the Company’s primary focus is on ‘businesses that are technology-enabled.’ All forward-looking assertions concerning potential business combinations and related financing were attributed to the Company’s management team. Personnel disclosures identify Yuming Zou as Chief Financial Officer and list Von Lam as the investor relations contact at 136 Madison Avenue, 6th Floor, New York, NY 10016 (telephone area code 646, local number 722-3311). For investors tracking capital deployment mechanics, this filing documents a routine post-offering liquidity event that unlocks independent pricing for the equity and option tranches without disturbing the underlying trust reserve or resetting the search timeline. Because the filing leaves the redemption window, target pipeline status, and termination date untouched, it signals operational continuity rather than a inflection point; investors should continue monitoring periodic reports for de-SPAC announcements, amendment filings, or sponsor commitment updates.

What changed: A routine compliance exhibit — specifically, a Joint Filing Agreement (Exhibit 99.1) attached to a Schedule 13D, executed on February 9, 2026, by Muzero Acquisition Sponsors LLC, Von Lam, and Yuming Zou. The document establishes that these three parties represent they are eligible to jointly report beneficial ownership of Muzero Acquisition Corp’s Class A ordinary shares, $0.0001 par value. The agreement, as drafted by the parties, mutually assigns each signatory responsibility for the timeliness, completeness, and accuracy of the Schedule 13D filing and any amendments. Bearing on investor mechanics, the filing discloses no share counts, trust adjustments, redemption elections, extension proposals, deal progress, or sponsor conduct updates. The parties did not report any intention to convert shares, solicit proxies, or pursue an initial business combination. The agreement leaves the stated February 2, 2028 conversion deadline and the $10.15 per-share trust value entirely unaffected. Why it matters: Investors monitoring redemption calendars, trust preservation, and sponsor alignment should recognize that joint filing agreements typically indicate the formation or formal acknowledgment of a reporting group under Section 13(d) of the Exchange Act. While this exhibit contains no claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, the coordinated execution signals potential unified action ahead of critical SPAC milestones such as shareholder votes on an initial business combination, trust extension ballots, or conversion/redemption decisions. Because the parties explicitly state in the agreement that each assumes liability for information about the others only to the extent they know or have reason to believe it is accurate, the verification of collective leverage rests with the individual signatories. Market participants must track subsequent Schedule 13D amendments to discover if beneficial ownership reaches statutory thresholds, shifts sponsor control dynamics, or outlines acquisition strategies that would directly impact redemption pressure or trust liquidation timing.

What changed: A Form 8-K Current Report and accompanying audited balance sheet announcing the consummation of Muzero Acquisition Corp’s initial public offering and private placement on February 2, 2026. Item 8.01 reports that the company closed its IPO of 20,125,000 units (including the full exercise of a 2,625,000-unit over-allotment option) and simultaneously closed a private sale of 486,875 private placement units. The audited balance sheet dated February 2, 2026, records $201,250,000 deposited into a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, reflecting the company’s stated allocation of $10.00 per unit. Note 1 establishes a 24-month completion window to find a business combination, after which public shares are redeemable. The sponsor, Muzero Acquisition Sponsors LLC, purchased 335,938 private units, while BTIG, LLC purchased 150,937. The underwriting agreement stipulates a $7,043,750 deferred underwriting discount payable solely upon business combination completion, and Note 6 details warrant mechanics including a $11.50 exercise price, exercisability beginning 30 days post-combination, and an $18.00 per-share cash redemption trigger. The sponsor letter agreement waives redemption rights for founder and private shares and provides indemnification to protect the trust balance against third-party claims reducing it below the lesser of $10.00 per public share or the actual per-share trust amount at liquidation. Why it matters: Note 1 confirms that as of February 2, 2026, management had neither selected a target nor engaged in substantive discussions regarding an initial business combination, meaning the 24-month timeline (expiring February 2, 2028) is advancing without offsetting de-risking events. The disclosed $10,649,942 in transaction costs and $1,349,169 in non-trust cash reserves outline pre-combination liquidity constraints, while the provision allowing tax releases from trust interest and up to $100,000 of interest for dissolution expenses could subtly adjust final per-share redemption amounts. Founder share transfer details (280,000 shares assigned to directors/officers at a $2.46 per share fair value) and the $15,000 monthly administrative services fee disclose ongoing sponsor compensation and potential dilution vectors. By cementing these parameters, the document provides the exact contractual framework needed to model future extension requests, tender offer thresholds, and sponsor alignment metrics before any target disclosure materializes.

What changed: SEC Form 4 – Routine compliance exhibit and insider ownership report. Muzero Acquisition Sponsors LLC, Director and Chief Executive Officer Lam Von Villy Mendoza, and Chief Financial Officer Zou Yuming filed a Form 4 disclosing open-market acquisitions of 335,938 shares at $10 per share on February 2, 2026. Post-transaction, their aggregate beneficial ownership totals 7,044,271 shares. Why it matters: The filing records sponsor and executive accumulation during the SEARCHING phase, which raises direct equity alignment but does not alter the business combination timeline, trigger a trust account modification, or create an extension. Investors tracking the fixed redemption deadline of February 2, 2028, will note that this disclosure adds no amendment to the closing schedule, preserves the previously reported trust balance of $10.15 per share, and contains no target pipeline updates, acquisition letter of intent, or deal-progression markers. The Form 4 includes zero forward-looking assertions regarding customer contracts, recurring revenue, total addressable market sizing, proprietary technology, strategic partnerships, active litigation, or executive departures. Sponsor purchasing of this scale primarily serves as a capital-positioning signal ahead of any future deSPAC execution, carrying no contractual force to consummate a merger or defend the trust floor.

What changed: 8-K Current Report filed by Muzero Acquisition Corp on 2026-02-03, reporting the consummation of its initial public offering (IPO) on February 2, 2026, including full exercise of the underwriters' over-allotment option, and the entry into related definitive agreements, appointment of directors and officers, amendment of charter, and deposit of proceeds into the trust account. The SPAC completed its IPO of 20,125,000 units at $10.00 per unit, raising gross proceeds of $201,250,000 (including full exercise of the over-allotment option). Simultaneously, private placements of 486,875 units to Sponsor (335,938 units) and BTIG (150,937 units) raised additional gross proceeds of $4,868,750. The trust account was funded with $201,250,000 (including $7,043,750 in deferred underwriting fees). Trust value per public share is $10.00. The deadline to complete a business combination is 24 months from IPO closing (February 2, 2028) as per the amended charter. The company entered into standard IPO agreements: Underwriting Agreement (BTIG), Warrant Agreement (Continental), Investment Management Trust Agreement, Registration Rights Agreement, Private Placement Unit Purchase Agreements with Sponsor and BTIG, Letter Agreement (lock-ups, voting, etc.), Administrative Services Agreement ($15,000/month), and Indemnity Agreements. Directors were appointed (Sheldon Trainor-DeGirolamo, Patrick Aber, Hope Ni, Derek Reisfield) and officers named (Patrick Aber as COO, Steven Maksymyk as Chief Strategy Officer). The company confirms no specific target has been selected and no substantive discussions initiated. The 8-K also files the amended and restated memorandum and articles of association. Why it matters: This filing establishes the SPAC's capital structure, trust account mechanics, governance, and contractual framework. It confirms the trust per-share value at $10.00, the 24-month deadline (February 2028), and the absence of any pre-selected target. Investors can now track redemption deadlines, monitor trust value changes from interest, and assess sponsor conduct under the lock-up and voting agreements. The IPO proceeds are now held in trust pending a business combination.

What changed: 424B4 prospectus for the initial public offering of Muzero Acquisition Corp, a blank-check SPAC. This is the final prospectus for MUZE's IPO, setting the terms of the offering: 17,500,000 units at $10.00/unit, $175 million in trust ($10.15/share as of filing date), 24-month deadline to February 2028, with a 15% redemption cap per shareholder if a vote is held, and no target selected. The document also discloses that the independent auditor's report contains a going concern qualification. Why it matters: This is the definitive IPO document for a new SPAC. It sets all the mechanical terms investors need to track: trust value per share ($10.15 as of this filing), redemption mechanics (available regardless of vote, 15% cap if shareholder vote held), deadline structure (24 months from closing, extendable with shareholder vote), sponsor economics ($0.004/share for founder shares vs $10.00 for public), and the significant dilution public shareholders face. It also confirms no target discussions have occurred.

What changed: SEC Form 3—insider ownership report. Director and Chief Operating Officer Patrick John Aber filed a standard Form 3 confirming that no non-derivative transactions or holdings were reported for the applicable period. Why it matters: This routine compliance exhibit does not alter the redemption deadline of 2028-02-02, adjust the $10.15 trust value per share, or indicate business combination progress while the issuer remains in SEARCHING status. Regarding sponsor conduct and insider alignment, the filing confirms the COO/director neither accumulated nor divested equity during the reporting window, providing no actionable signal regarding impending mergers, extension votes, or redemption campaigns. The document contains no substantive claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel transitions. All details are attributed directly to the submitted Form 3.

What changed: This is a Form 8-A filing submitted to register three classes of securities—Units (each comprising one Class A ordinary share and one-half of one redeemable warrant), Class A ordinary shares with a par value of $0.0001, and whole redeemable warrants exercisable at an exercise price of $11.50—for quotation on The Nasdaq Stock Market LLC pursuant to Section 12(b) of the Exchange Act. As a routine administrative compliance exhibit, the filing adds these security classes to the SEC registry and explicitly incorporates their detailed terms by reference from the Registration Statement on Form S-1 (File No. 333-291923) originally filed on December 3, 2025. Chief Executive Officer Von Lam executed the registration on January 29, 2026. The filing introduces no modifications to warrant strike prices, redemption mechanics, trust funding protocols, extension provisions, or the business combination timeline. Why it matters: For investors tracking redemption deadlines, trust allocation, extensions, deal progress, and sponsor conduct, this submission confirms the procedural rails for public trading without altering the trust balance or termination date currently tracked in your coverage. Because the document contains zero claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or executive compensation beyond the signature block, it does not adjust the redemption window or introduce new deal catalysts. Its practical effect is limited to cementing the $11.50 warrant exercise price in the public record and satisfying Exchange Act reporting prerequisites ahead of any prospective de-SPAC transaction.